Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Part D Off-Label Prescription Parity Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2011 · fourth_quarter · Q4
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Source: Senate LDA
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Drug Safety Enhancement Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act
Drug Safety Enhancement Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Drug Safety Enhancement Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Airport and Airway Extension Act of 2011, Part II
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Airport and Airway Extension Act of 2011, Part II
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Airport and Airway Extension Act of 2011, Part II
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 1893 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Medicare Drug Savings Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Medicare Drug Savings Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Medicare Drug Savings Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Preserving Access to Life-Saving Medications Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Preserving Access to Life-Saving Medications Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Cancer Drug Coverage Parity Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Cancer Drug Coverage Parity Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Medication Therapy Management Benefits Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Medication Therapy Management Benefits Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Medication Therapy Management Benefits Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Proposed changes to the Medicare Part D prescription drug benefit: modifying current Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse; legislation that would expand the current medication therapy management program in Part D (S 274/HR 891)
Medication Therapy Management Benefits Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
Medicare Prescription Drug Savings and Choice Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Medicare Prescription Drug Savings and Choice Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Medicare Prescription Drug Savings and Choice Act of 2011
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
Pharmaceutical Market Access Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.
Wired for Health Care Quality Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.
Generic Prescription Drug Fairness Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
"Conscience Clause" Bills (HR1539/HR1652/S809); Generic Drugs (S1903/S2300/S3582); Prescription Drug Importation; Counterfeit Drugs
Lower PRICED Drugs Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
"Conscience Clause" Bills (HR1539/HR1652/S809); Generic Drugs (S1903/S2300/S3582); Prescription Drug Importation; Counterfeit Drugs
Pharmaceutical Market Access and Drug Safety Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.
Preserve Access to Affordable Generics Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
"Conscience Clause" Bills (HR1539/HR1652/S809); Generic Drugs (S1903/S2300/S3582); Prescription Drug Importation; Counterfeit Drugs
Medicare Data Access and Research Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare/Medicaid Reform; Medicare Modernization Act Amendments; "The Medicare Data Access and Research Act" (S3897)
Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.
Access to Legal Pharmaceuticals Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
"Conscience Clause" Bills (HR1539/HR1652/S809); Generic Drugs (S1903/S2300/S3582); Prescription Drug Importation; Counterfeit Drugs
Food and Drug Administration Safety Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.
Providing for consideration of the bill (H.R. 376) to amend title XVIII of the Social Security Act to authorize the Secretary of Health and Human Services to negotiate fair prices for Medicare prescription drugs on behalf of Medicare beneficiaries.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Pharmaceutical Market Access Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Efficiency in Government Health Care Spending Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Medicare Value Purchasing Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Wired for Health Care Quality Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Dylan Lee James Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Medicare Enhancements for Needed Drugs Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Pharmaceutical Market Access and Drug Safety Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Medicare Prescription Drug Savings and Choice Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Medicare Prescription Drug Price Reduction Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
National All Schedules Prescription Electronic Reporting Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Patient Safety and Quality Improvement Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Medicare Prescription Drug Savings and Choice Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
Food and Drug Administration Safety Act of 2005
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Supporting a National Charter Schools Week.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
HR 2112 - appropriations legislation covering the Food and Drug Administration.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2011 · third_quarter · Q3
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
HR 2112 - appropriations legislation covering the Food and Drug Administration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2011 · second_quarter · Q2
HR 2112 - appropriations legislation covering the Food and Drug Administration. Also discussed topic of FDA funding generally with Senate staff.
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
HR 1893 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2011 · first_quarter · Q1
Proposed changes to the Medicare Part D prescription drug benefit: modifying current Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse; legislation that would expand the current medication therapy management program in Part D (S 274/HR 891)
Increased funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing, appropriations for the U.S. Food and Drug Administration
Granting independent pharmacists collective bargaining rights/antitrust exemption
Legislation relating to pharmacy issues and the professional role of pharmacists, legislation relating to medication therapy management programs and funding for such programs, legislation relating to the importation of prescription drugs, legislation relating to settlement agreements between brand-name and generic manufacturers, legislation promoting the use of generic drugs generally, legislation relating to pharmacy benefit managers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2010 · fourth_quarter · Q4
Legislation that would grant independent pharmacists collective bargaining rights/antitrust exemption
Increased funding for comparative effectiveness research; legislation relating to health information technology and electronic prescribing, appropriations for the U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality
Proposed changes to Medicare Part D prescription drug benefit; modifying current Medicare Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse.
Legislation relating to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs and funding for such programs, legislation relating to the importation of prescription drugs, legislation relating to settlement agreements between brand-name and generic manufacturers, legislation promoting the use of generic drugs generally, legislation relating to pharmacy benefit managers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2010 · third_quarter · Q3
Proposed changes to the Medicare Part D prescription drug benefit; modifying current Medicare Part D prompt payment rules for pharmacies in order to better combat fraud, waste and abuse
increased funding for comparative effectiveness research; legislation relating to health information technology and electronic prescribing; appropriations for the U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality
Legislation that would grant independent pharmacists collective bargaining rights/antitrust exemption.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2010 · second_quarter · Q2
Legislation that would grant independent pharmacists collective bargaining rights
Legislation relating to to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs and funding for said programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
Health care reform legislation with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing; appropriations for the U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2010 · first_quarter · Q1
Proposed changes to the Medicare Part D prescription drug benefit. Adjustment to Medicaid prescription drug reimbursement rates.
Legislation that would grant independent pharmacists collective bargaining rights.
Health care reform legislation with respect to pharmacy issues and the professional role of pharmacists; legislation related to medication therapy management programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2009 · fourth_quarter · Q4
Proposed changes to the Medicare Part D prescription drug benefit. Adjustment to Medicaid prescription drug reimbursement rates.
Health care reform with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation reslating to health information technology and electronic prescribing; appropriations for U.S. Food and Drug Administrations and the Agency for Healthcare Research and Quality.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2009 · third_quarter · Q3
Legislation granting independent pharmacists collective bargaining rights.
Proposed changes to the Medicare Part D prescription drug benefit. Adjustment to Medicaid prescription drug reimbursement rates.
Health care reform with respect to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2009 · second_quarter · 2A
Proposed changes to the Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.
Health care reform with respect to pharmacy issues and the professional role of pharmacists in health care reform; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing.
Legislation granting independent pharmacists collective bargaining rights.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2009 · first_quarter · 1A
Legislation granting independent pharmacists collective bargaining rights.
Proposed changes to the Medicare Part D prescripion drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to coordinate comparative effectiveness research, legislation relating to health information technology and elecronic prescribing; the professional role of pharmacists in health care reform
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2009 · second_quarter · Q2
Legislation granting independent pharmacists collective bargaining rights.
Establishing a regulatory pathway for FDA approval of follow-on biologic products; electronic prescribing of controlled substances and generally; regulation of online pharamcies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research
Proposed changes to the Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2009 · first_quarter · Q1
Proposed changes to the Medicare Part D prescripion drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.
Establishing a regulatory pathway for FDA approval of follow-on biologics products; electronic prescribing of controlled substances and generally; regulation of online pharmacies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to coordinate comparative effectiveness research, legislation relating to health information technology and elecronic prescribing; the professional role of pharmacists in health care reform
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · fourth_quarter · 4A
Proposed changes to Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to perform comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances and generally, regulation of online pharmacies, importation of prescription drugs, federal funding for academic detailing programs, promotion of the use of generic drugs
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · third_quarter · 3A
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, eletronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
Proposed changes to Medicare Part D prescription drug benefit (Medicare Improvements for Patients and Providers Act of 2008). Adjustments to Medicaid prescription drug reimbursement rates.
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · second_quarter · 2A
Proposed changes to Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates (calculation of average manufacturer's price).
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing.
Legislation granting independent and community pharmacists collective bargaining rights.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · first_quarter · 1A
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, Electronic prescribing of controlled substances, Regulation of online pharmacies, Importation of prescription drugs.
Proposed changes to the Medicare Part D prescription drug benefit. Adjustments to Medicare prescription drug reimbursement rates (calculation of average manufacturer's price).
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · fourth_quarter · Q4
Legislation granting independent pharmacists collective bargaining rights.
Increased federal funding for comparative effectiveness research, establishment of a public-private entity to perform comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances and generally, regulation of online pharmacies, importation of prescription drugs, federal funding for academic detailing programs, promotion of the use of generic drugs
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · third_quarter · Q3
Legislation granting independent pharmacists collective bargaining rights
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, eletronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · second_quarter · Q2
Proposed changes to Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates (calculation of average manufacturer's price).
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · second_quarter · RR
Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including establishment of a regulatory pathway for approval of "follow-on" biologic drug products, additional monitoring of direct-to-consumer advertisements of prescription drugs and additional agency funding; funding for comparative effectiveness research; health information technology/e-prescribing; importation of prescription drugs/counterfeit drugs
Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including establishment of a regulatory pathway for approval of "follow-on" biologic drug products, additional monitoring of direct-to-consumer advertisements of prescription drugs and additional agency funding; funding for comparative effectiveness research; health information technology/e-prescribing; importation of prescription drugs/counterfeit drugs
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2008 · first_quarter · Q1
Proposed changes to the Medicare Part D prescription drug benefit. Adjustments to Medicare prescription drug reimbursement rates (calculation of average manufacturer's price).
Legislation granting independent and community pharmacies collective bargaining rights.
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, Electronic prescribing of controlled substances, Regulation of online pharmacies, Importation of prescription drugs.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2007 · mid_year · RR
Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including additional monitoring of direct-to-consumer advertisements for prescription drugs and additional agency funding; legislation relating to "follow-on" biologic pharmaceuticals; legislation relating to authorized generic prescription drugs; importation of prescription drugs/counterfeit drugs; funding for comparative effectiveness research; health information technology/e-prescribing
Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including additional monitoring of direct-to-consumer advertisements for prescription drugs and additional agency funding; legislation relating to "follow-on" biologic pharmaceuticals; legislation relating to authorized generic prescription drugs; importation of prescription drugs/counterfeit drugs; funding for comparative effectiveness research; health information technology/e-prescribing
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2007 · year_end · YY
Proposed changes to the Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates (calculation of average manufacturer price).
Increased funding for comparative effectiveness research. Legislation related to health information technology and electronic prescribing.
Prescription Drug User Fee Act (PDUFA) re-authorization. Food and Drug Administration reform efforts: expansion of post-market surveillance programs for prescription drugs; post-market risk management; additional monitoring of direct-to-consumer advertisements for prescription drugs; additional agency funding.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2007 · mid_year · MM
* Prescription Drug User Fee Act (PDUFA) re-authorization Food and Drug Administration reform efforts: expansion of post-market surveillance programs for prescription drugs; post-market risk management; additional monitoring of direct-to-consumer advertisements for prescription drugs; additional agency funding. Adjustments to Medicaid prescription drug reimbursement rates (calculation of average manufacturer price). Legislation relating to "follow-on" biologic pharmaceuticals. Legislation relating to authorized generic prescription drugs. Importation of prescription drugs/counterfeit drugs. Federal regulation of the practice of pharmacy compounding,
Proposed changes to Medicare Part D prescription drug benefit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2006 · year_end · YY
Medicare/Medicaid Reform; Medicare Modernization Act Amendments; "The Medicare Data Access and Research Act" (S3897)
Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.
"Conscience Clause" Bills (HR1539/HR1652/S809); Generic Drugs (S1903/S2300/S3582); Prescription Drug Importation; Counterfeit Drugs
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2006 · year_end · RA
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2006 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2005 · year_end · YY
Access to Generic Drugs; Prescription Drug Importation; Counterfeit Drugs
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exlusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2005 · year_end · YA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2005 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2004 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2004 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2002 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2002 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2001 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2001 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation relating to pharmacy issues and the professional role of pharmacists; legislation relating to medication therapy management programs and funding for such programs; legislation relating to the importation of prescription drugs; legislation relating to settlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally; legislation regulating pharmacy benefit managers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposed changes to the Medicare Part D prescription drug benefit; adjustment to Medicaid prescription drug reimbursement rates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform legislation with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing; appropriations for U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform with respect to pharmacy issues and the professional role of pharmacists; legislation related to medication therapy management programs; legislation relating to importation of prescription drugs; legislation granting the FDA authority to approve follow-on biologic products; legislation relating to setlement agreements between brand-name and generic manufacturers; legislation promoting the use of generic drugs generally.
Legislation that would grant independent pharmacists collective bargaining rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform with respect to pharmacy issues and the professional role of pharmacists; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effetiveness research; legislation relations to health information technology and elecrtonic prescribing; appropriations for U.S. Food and Drug Administration and the Agency for Healthcare Research and Quality.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform with respect to pharmacy issues and the professional role of pharmacists in health care reform; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Establishing a regulatory pathway for FDA approval of follow-on biologics products; electronic prescribing of controlled substances and generally; regulation of online pharmacies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform with respect to pharmacy issues and the professional role of pharmacists in health care reform; increased federal funding for comparative effectiveness research; establishment of a public-private entity to coordinate comparative effectiveness research; legislation relating to health information technology and electronic prescribing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation granting independent pharmacists collective bargaining rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation granting independent pharmacists collective bargaining rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation granting independent pharmacists collective bargaining rights
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Establishing a regulatory pathway for Food and Drug Administration approval of follow-on biologic products, electronic prescribing of controlled substances, regulation of online pharmacies, importation of prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation granting independent and community pharmacies collective bargaining rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposed changes to Medicare Part D prescription drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposed changes to Medicare Part D prescription drug benefit (Medicare Improvements for Patients and Providers Act of 2008). Adjustments to Medicaid prescription drug reimbursement rates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation granting independent and community pharmacists collective bargaining rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including establishment of a regulatory pathway for approval of "follow-on" biologic drug products, additional monitoring of direct-to-consumer advertisements of prescription drugs and additional agency funding; funding for comparative effectiveness research; health information technology/e-prescribing; importation of prescription drugs/counterfeit drugs
Increased federal funding for comparative effectiveness research, legislation relating to health information technology and electronic prescribing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposed changes to the Medicare prescription drug benefit; adjustments to Medicaid prescription drug reimbursement rates; FDA issues, including additional monitoring of direct-to-consumer advertisements for prescription drugs and additional agency funding; legislation relating to "follow-on" biologic pharmaceuticals; legislation relating to authorized generic prescription drugs; importation of prescription drugs/counterfeit drugs; funding for comparative effectiveness research; health information technology/e-prescribing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE